Ambrx Biopharma, Inc. Quarterly Liabilities and Equity in USD from Q4 2022 to Q3 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary: Ambrx Biopharma, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2022 to Q3 2023.
Ambrx Biopharma, Inc. Liabilities and Equity for the quarter ending September 30, 2023 was $272M.

Liabilities and Equity, Quarterly (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q3 2023	$272M			Sep 30, 2023	10-Q	2023-11-13
Q4 2022	$147M			Dec 31, 2022	10-Q	2023-11-13

* An asterisk sign (*) next to the value indicates that the value is likely invalid.